May 6, 2019 05:06 PM EDTUpdated May 6, 08:11 PM
R&D

GW Phar­ma scores an­oth­er PhI­II win for its cannabi­noid in rare form of epilep­sy

John Carroll

Editor & Founder

GW Phar­ma­ceu­ti­cals can now boast about its fifth straight suc­cess­ful Phase III tri­al for its cannabi­noid drug Epid­i­olex.

Re­searchers for the biotech said Mon­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times